Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Illumina, Inc. (ILMN)

Nasdaq Health Care Life Sciences Tools & Services S&P 500
$213.13
+5.13 (+2.47%)
Close of Nov 06, 2026 · end-of-day data
Source: Illumina, Inc.'s 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 02, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2017FY2017FY2018FY2019FY2021FY2022FY2023FY2023FY2024FY2025
Revenue$2.40B$2.75B$3.33B$3.54B$3.24B$4.53B$4.58B$4.50B$4.37B$4.34B
Cost of revenue$732.00M$926.00M$1.03B$1.08B$1.04B$1.37B$1.61B$1.76B$1.51B$1.47B
Gross profit$1.67B$1.83B$2.30B$2.47B$2.20B$3.15B$2.97B$2.74B$2.86B$2.87B
Research & development$504.00M$546.00M$623.00M$647.00M$682.00M$1.19B$1.32B$1.35B$1.17B$967.00M
Selling, general & admin$584.00M$674.00M$794.00M$835.00M$941.00M$2.09B$1.30B$1.61B$1.09B$1.09B
Operating income$587.00M$606.00M$883.00M$985.00M$580.00M-$123.00M-$4.18B-$1.07B-$833.00M$807.00M
Interest expense$33.00M$37.00M$57.00M$52.00M$49.00M$61.00M$26.00M$77.00M$100.00M$101.00M
Pre-tax income$561.00M$1.04B$894.00M$1.12B$856.00M$884.00M-$4.34B-$1.12B-$1.18B$1.09B
Income tax$133.00M$365.00M$112.00M$128.00M$200.00M$122.00M$68.00M$44.00M$44.00M$236.00M
Net income$463.00M$726.00M$826.00M$1.00B$656.00M$762.00M-$4.40B-$1.16B-$1.22B$850.00M
EBITDA$728.00M$762.00M$1.06B$1.17B$767.00M$128.00M-$3.79B-$637.00M-$479.00M$1.08B
EPS (basic)$3.09$4.96$5.63$6.81$4.48$5.07$-28.00$-7.34$-7.69$5.47
EPS (diluted)$3.07$4.92$5.56$6.74$4.45$5.04$-28.00$-7.34$-7.69$5.45
Diluted shares148.00M148.00M149.00M149.00M148.00M151.00M157.00M158.00M159.00M156.00M
Gross margin69.5%66.4%69.0%69.6%68.0%69.7%64.8%60.9%65.4%66.1%
Operating margin24.5%22.0%26.5%27.8%17.9%-2.7%-91.2%-23.7%-19.1%18.6%
Net margin19.3%26.4%24.8%28.3%20.3%16.8%-96.1%-25.8%-28.0%19.6%

Balance sheet

fiscal years · USD
Fiscal yearFY2017FY2017FY2018FY2019FY2021FY2022FY2023FY2023FY2024FY2025
Cash & equivalents$735.00M$1.23B$1.14B$2.04B$1.81B$1.23B$2.01B$1.05B$1.13B$1.42B
Short-term investments$824.00M$920.00M$2.37B$1.37B$1.66B$107.00M$26.00M$6.00M$93.00M$215.00M
Receivables$381.00M$411.00M$514.00M$573.00M$487.00M$648.00M$671.00M$734.00M$735.00M$854.00M
Inventory$300.00M$333.00M$386.00M$359.00M$372.00M$431.00M$568.00M$587.00M$547.00M$564.00M
Total current assets$2.32B$2.98B$4.49B$4.45B$4.48B$2.71B$3.56B$2.61B$2.75B$3.29B
Goodwill$776.00M$771.00M$831.00M$897.00M$897.00M$7.11B$3.24B$2.54B$1.11B$1.11B
Total assets$4.28B$5.26B$6.96B$7.32B$7.58B$15.22B$12.25B$10.11B$6.30B$6.64B
Total current liabilities$705.00M$746.00M$1.80B$665.00M$1.24B$1.09B$2.77B$1.57B$1.55B$1.58B
Short-term debt$2.00M$10.00M$1.11B$0$511.00M$0————
Long-term debt$1.06B$1.18B$890.00M$1.14B$673.00M—————
Total debt$1.06B$1.19B$2.00B$1.14B$1.18B$0————
Total liabilities$2.08B$2.51B$3.20B$2.70B$2.89B$4.48B$5.65B$4.37B$3.93B$3.92B
Shareholders' equity$2.20B$2.75B$3.76B$4.61B$4.69B$10.74B$6.60B$5.75B$2.37B$2.72B

Cash flow

fiscal years · USD
Fiscal yearFY2017FY2017FY2018FY2019FY2021FY2022FY2023FY2023FY2024FY2025
Operating cash flow$779.00M$875.00M$1.14B$1.05B$1.08B$545.00M$392.00M$478.00M$837.00M$1.08B
Capital expenditures$260.00M$310.00M$296.00M$209.00M$189.00M$208.00M$286.00M$195.00M$128.00M$148.00M
Free cash flow$519.00M$565.00M$846.00M$842.00M$891.00M$337.00M$106.00M$283.00M$709.00M$931.00M
Investing cash flow-$515.00M-$214.00M-$1.81B$745.00M-$554.00M-$1.07B-$591.00M-$231.00M-$178.00M-$55.00M
Financing cash flow-$296.00M-$176.00M$594.00M-$897.00M-$766.00M-$51.00M$1.00B-$1.21B-$570.00M-$744.00M
Share buybacks$249.00M$251.00M$201.00M$324.00M$736.00M$0$0$0$116.00M$742.00M
Stock-based compensation$129.00M$164.00M$193.00M$194.00M$194.00M$754.00M$366.00M$380.00M$370.00M$275.00M
Depreciation & amortization$141.00M$156.00M$179.00M$188.00M$187.00M$251.00M$394.00M$432.00M$354.00M$270.00M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.